-
A new breakthrough in photodynamic therapy! The new device is safe and effective in killing tumors
Time of Update: 2021-02-06
Scientists from Waseda University, japan's National University of Defense Medicine and the Japan Science and Technology Agency have developed a new bio-adhesive wireless energy-powered light-emitting
-
Simple testing of disease-carrying mosquitoes proves the presence of bio-pesticides
Time of Update: 2021-02-06
Researchers at the University of Texas at Austin have developed a new diagnostic tool to quickly and cheaply determine whether mosquitoes belong to species that carry dangerous diseases such as Zika virus, dengue, chikungi or yellow fever.
-
Improving genetic disease Antisypolytic drugs can reduce the "pathogenic" lipoproteins in cardiovascular patients
Time of Update: 2021-02-06
The occurrence of plate levels below normal (140,000/mm3) was comparable in the active treatment group (10.5%) and placebo (14.9%); Andis o'Dea, Chief Medical Officer, Akcea, said, "These data show that AKCEA-APO(a)-LRx significantly lowers its Lp(a) levels in patients with cardiovascular disease due to elevated Lp(a) levels." This is the first and only drug shown to significantly reduce Lp(a) levels clinically and has good safety and tolerance in patients with this genetic disease.
-
The Japanese research team successfully deciphered the Hydrangea genome
Time of Update: 2021-02-06
Kyodo News reported on October 31st that a joint research team from Kyusju University of Technology and Tokyo Women's Medical University published results in the online edition of the British Journal of Science on Wednesday, successfully deciphering the hydrangea genome, which has been used in traditional Chinese medicine since ancient times and is also known as the "magic mushroom", confirming that it contains ingredients similar to those found to be effective in suppressing atherosclerosis.
-
Genetic engineering helps researchers overcome two major immune barriers to gene therapy
Time of Update: 2021-02-06
However, using an engineered DNA structure that encodes tiny antimyostrophy proteins can significantly reduce the body's immune response to antimyotrophy proteins and AAV-6 vectors in mice.
-
Single-drug first-line treatment AML has significant efficacy The first FLT3 targeted inhibitor applied for market
Time of Update: 2021-02-06
The application is based on data from QuANTUM-R, a key randomized Phase III clinical study conducted in the United States, the European Union, Asia (excluding Japan), and an open label single-group Phase II study of adult patients treating relapse/recurring FLT3-ITD AML conducted in Japan.
-
Pioneering and innovative cancer cell therapy, Roche Expanded Cooperation Agreement
Time of Update: 2021-02-06
Today, SQZ Biotech, Massachusetts, announced an expanded partnership with Roche to use its SQZ platform to develop anti-cancer cell therapies based on antigen delivery cells (APCs).
-
New advances in prostate cancer New York University's targeted therapy for synthetic Wnt pathlands
Time of Update: 2021-02-06
In the experiment, the researchers found that ring peptides blocked overactive β-linked proteins interacted with TCF, allowing zebrafish to develop eyes, an interaction similar to the one that affects prostate cancer in humans.
-
Subvert tradition! Mutations at the same point can have different effects
Time of Update: 2021-02-06
According to a new study by the University of Eastern Finland, the effects of KRAS mutations vary widely among many different tumors.
study is the first to reveal the effects of different mutations at the same location on the level function of kras proteins.
-
K medicine mighty! Mercedon Keytruda single-drug first-line treatment for PD-L1-positive lung cancer was approved by the FDA for priority examination:
Time of Update: 2021-02-06
KEYNOTE-042 is an international, randomized, open-label study (NCT02220894) that assessed the efficacy and safety of truKeyda as a single-drug therapy relative to platinum-containing chemotherapy in patients with local late stage or metastasis PD-L1 positive (TPS≥1%) NSCLC (including non-scale and squamous histological types).
-
Scientists find 'total switch' to control malignant breast cancer
Time of Update: 2021-02-06
In a recent study published in the international journal Lancer Cell, scientists from the Salk Institute identified a special "total switch" that appears to control the dynamic behavior of tumor cells
-
Advanced computational methods accelerate the development of drug-targeted therapy
Time of Update: 2021-02-06
"Compared to traditional drug discovery pipelines, CRAFT provides an efficient data-driven approach based on a systematic genetic framework that allows the identification of the gene network that drives the disease and its main control point in a record time - the strategic subjects we implement here to predict membranes as effective drug targets that can then be experimentally validated at the earliest stages of the drug discovery process," the authors explain.
-
Resynation of neurons is enough to relieve schizophrenia
Time of Update: 2021-02-06
Recently, researchers from the University of Geneva in Switzerland made exciting progress in this regard by discovering a molecular mechanism that causes the desynotation of neural networks and successfully repairing this tissue defect in adult animal models, thereby suppressing abnormal behavior associated with schizophrenia.
-
Artificial intelligence helps new wearables monitor the heart more accurately
Time of Update: 2021-02-06
A start-up set up by researchers has developed a low-cost new wearable device that monitors heart and cardiovascular function, using artificial intelligence to analyze heart rate and breathing problem
-
Chinese scholars have found anti-cancer targets to control the lifeblood of gliomas in the brain
Time of Update: 2021-02-06
"We have found that inhibiting this gene may inhibit the ability of tumor stem cells to self-renew and differentiate into glioma cells, which are considered to be one of the characteristics of this type of hard-to-treat cancer." "Sheng said." Although more research is needed before a new treatment can be designed, our early basic research is promising.
-
Scientists illustrate the key role of alkaline granulocytes in lung development!
Time of Update: 2021-02-06
Adults' lungs are made up of many highly specific cell types that are protected by a variety of immune cells, so how do these immune cells migrate to the lungs after birth and during development? How
-
The new base editor is expected to treat genetic diseases
Time of Update: 2021-02-06
The findings were published in the October 2018 issue of the journal Nature Medicine under the title "Treatment of a metabolic liver disease by vivo genome base editing in adult mice".
-
Combined CK2 inhibitors and immuno-checkpoint inhibitors eliminate a variety of tumors
Time of Update: 2021-02-06
" based on these findings, Dr. Gabrilovich and his colleagues began looking at whether CK2 inhibitors and immuno-checkpoint inhibitors could be combined to enhance their anti-tumor effectiveness." Our new results suggest that using a CK2 inhibitor to manipulate the tumor microencase may make patients more sensitive to immuno-checkpoint inhibitors, thereby improving their clinical efficacy, although we still need to confirm them in clinical trials.
-
Leukemia farewell chemotherapy! Roche/AbbVie combination therapy Venclyxto-Gazyvaro first-line treatment with commodronation CLL:
Time of Update: 2021-02-06
AbbVie and Roche recently jointly announced positive results for the evaluation of CLL14 in a Phase III clinical study evaluating Venclexta/Venclyxto's combination therapy with Gazyva/Gazyvaro (obinutuzumab) for the first-line treatment of chronic lymphocytic leukemia (CLL).
-
Overcoming lung cancer-resistant Tagrisso promises new combination therapies
Time of Update: 2021-02-06
Blueprint Medicines today presented the positive results of two clinical proof-of-concept trials in patients with refractic non-small cell lung cancer (NSCLC) who carry EGFR mutations using the specific RET inhibitor BLU-667 in association with AstraZeneca's Tagrisso at the World Lung Cancer Congress of the International Lung Cancer Research Association.
